Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [3][10]. Core Insights - The company is expected to achieve its first annual profit in 2025, with projected revenue of at least 785 million RMB, representing a year-on-year growth of over 194% [7]. - The company has established itself as a rare AI pharmaceutical platform, with significant value realization expected in the coming years [7]. - The report highlights the company's strong performance in the first half of 2025, achieving revenue of 517 million RMB, a year-on-year increase of 402%, and a net profit of 83 million RMB, marking a turnaround from previous losses [7]. - The company is building a business ecosystem based on its AI pharmaceutical technology, which is expected to strengthen its competitive barriers [7]. - The report emphasizes the company's successful collaborations and innovations, including the approval of a clinical trial for a rare disease drug and the development of a comprehensive cancer prevention and treatment system [7]. Financial Projections - Revenue projections for the company are as follows: 2024A: 266 million RMB, 2025E: 785 million RMB, 2026E: 1,087 million RMB, and 2027E: 1,485 million RMB, with growth rates of 52.8%, 194.5%, 38.5%, and 36.6% respectively [2][8]. - The net profit forecast shows a turnaround from a loss of 1,517 million RMB in 2024 to a profit of 116 million RMB in 2025, with further projections of 5 million RMB in 2026 and 160 million RMB in 2027 [2][8]. - The earnings per share (EPS) is expected to improve from -0.35 RMB in 2024 to 0.03 RMB in 2025, reaching 0.04 RMB by 2027 [2][8].